MARKET

CRBP

CRBP

Corbus Pharms
NASDAQ

Real-time Quotes | Nasdaq Last Sale

4.920
+0.030
+0.61%
After Hours: 4.900 -0.02 -0.41% 17:52 12/11 EST
OPEN
4.870
PREV CLOSE
4.890
HIGH
4.960
LOW
4.820
VOLUME
376.75K
TURNOVER
--
52 WEEK HIGH
9.11
52 WEEK LOW
4.180
MARKET CAP
318.19M
P/E (TTM)
-4.8340
1D
5D
1M
3M
1Y
5Y

Buy or sell shares of CRBP and other stocks commission-free!

Open a Webull account and fund it to get a free stock

Analyst Rating

Based on 5 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

EPS

CRBP News

  • Corbus Pharmaceuticals to Host Expert Symposium on the Therapeutic Potential of Targeting the Endocannabinoid System
  • GlobeNewswire.2d ago
  • Corbus Pharma completes patient enrollment in mid-stage lenabasum study for CF
  • Seeking Alpha - Article.11/18 13:27
  • Corbus Pharmaceuticals Completes Enrollment of Phase 2b Study of Lenabasum for Treatment of Cystic Fibrosis
  • GlobeNewswire.11/18 13:17
  • Edited Transcript of CRBP earnings conference call or presentation 7-Nov-19 1:30pm GMT
  • Thomson Reuters StreetEvents.11/17 02:40

More

Industry

Biotechnology & Medical Research
-0.34%
Pharmaceuticals & Medical Research
+0.06%

Hot Stocks

Name
Price
%Change

About CRBP

Corbus Pharmaceuticals Holdings, Inc. is a Phase-III, clinical-stage pharmaceutical company focused on the development and commercialization of novel therapeutics to treat rare, chronic, and serious inflammatory and fibrotic diseases. The Company operates through developing and commercializing therapeutics to treat rare life-threatening inflammatory fibrotic diseases segment. The Company's lead product candidate, lenabasum, is a novel, synthetic oral endocannabinoid-mimetic drug designed to resolve chronic inflammation and halt fibrotic processes. Lenabasum stimulates the production of Specialized Pro-Resolving Lipid Mediators (SPMs) that act to resolve inflammation, and halt fibrosis by activating endogenous pathways. The Company is developing lenabasum to treat four diseases: systemic sclerosis, cystic fibrosis, diffuse cutaneous, skin-predominant dermatomyositis and systemic lupus erythematosus (SLE).
More

Webull offers Corbus Pharmaceuticals Holdings Inc (CRBP) stock price, real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, stock news, and many more online research tools to help you make informed decisions.